These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38810199)

  • 1. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Lanini S; Cai T; Tascini C
    N Engl J Med; 2024 May; 390(20):1937. PubMed ID: 38810199
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    van Os W; Zeitlinger M
    N Engl J Med; 2024 May; 390(20):1937-1938. PubMed ID: 38810200
    [No Abstract]   [Full Text] [Related]  

  • 3. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Manesh A; Varghese GM; Paterson DL
    N Engl J Med; 2024 May; 390(20):1938. PubMed ID: 38810201
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply.
    Wagenlehner FM; McGovern PC; Moeck G
    N Engl J Med; 2024 May; 390(20):1938-1939. PubMed ID: 38810202
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
    Moeck G; Gasink LB; Mendes RE; Woosley LN; Dorr M; Chen H; Wagenlehner FM; Henkel T; McGovern PC
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0023624. PubMed ID: 38780262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?
    Bassetti M; Giacobbe DR
    Med; 2024 May; 5(5):380-382. PubMed ID: 38733970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d.
    Granwehr B
    Ann Intern Med; 2024 Jun; 177(6):JC67. PubMed ID: 38830218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):117-118. PubMed ID: 39008106
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun.
    Trautner BW
    Clin Microbiol Infect; 2018 Sep; 24(9):929-930. PubMed ID: 29649605
    [No Abstract]   [Full Text] [Related]  

  • 13. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
    Hallgren H; Gustafsson I; Ripa T
    Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.
    Aguirre-Quiñonero A; Lecaroz Agara MC; Canut Blasco A
    Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1813-1815. PubMed ID: 29936620
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.
    Gentry LO; Rodriguez-Gomez G
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2371-4. PubMed ID: 1804010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.